Clinical Report: Association of PD-L1 with BRAFV600E Mutation in Ameloblastoma

Overview

Revise to specify the clinical relevance of CD8+ T cell infiltration in relation to PD-L1 expression.

Background

Ameloblastoma is a prevalent odontogenic tumor with a high recurrence rate and potential for malignant transformation. The BRAFV600E mutation is commonly found in AM, suggesting a role in tumor pathogenesis and potential targeted therapies. Understanding the immune microenvironment, particularly PD-L1 expression, may inform treatment strategies and improve patient outcomes.

Data Highlights

Key Findings

• 84% of AM patients showed PD-L1 positivity.
• 92.68% of BRAF mutation-positive cases were PD-L1 positive (p = 0.003).
• No significant correlation between PD-L1 and CD8+ T cells or FoxP3+ cells.
• High CD8+ T cell infiltration is associated with improved disease-free survival (HR = 0.112, p = 0.041).
• PD-L1 expression does not correlate with major clinicopathological parameters of AM.

Clinical Implications

The high prevalence of PD-L1 expression in BRAFV600E-mutated AM suggests that PD-L1 may serve as a potential therapeutic target. Additionally, assessing CD8+ T cell infiltration could provide prognostic information regarding disease-free survival, guiding treatment decisions.

Conclusion

The findings highlight the significant association between PD-L1 expression and the BRAFV600E mutation in ameloblastoma, with implications for targeted therapy and immunotherapy. Further studies are warranted to validate these results in larger cohorts.

Related Resources & Content

1. Blood Cancer Journal, 2015 -- BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis
2. Blood Cancer Journal, 2013 -- Lack of BRAF V600E mutation in human myeloma cell lines established from myeloma patients with extramedullary disease
3. Acta Neuropathologica, 2014 -- BRAF V600E Mutations Are Distinctive in Papillary Craniopharyngioma and May Occur Alongside CTNNB1 Mutations in Adamantinomatous Craniopharyngioma
4. Blood Cancer Journal, 2022 -- Implications for Treatment and Diagnosis of BRAF Fusions in Histiocytic Disorders
5. Precision therapy for BRAF V600E–mutated ameloblastoma: Systematic review insights - ScienceDirect
6. Molecular-targeted therapy in ameloblastoma: a systematic review - PMC
7. Programmed death-ligand 1 regulates ameloblastoma growth and recurrence
8. Contemporary management of ameloblastoma
9. Molecular-targeted therapy in ameloblastoma
10. Programmed death-ligand 1 regulates ameloblastoma growth and recurrence